HGH (Somatropin)

It acts both directly on tissues and, more importantly, by stimulating the liver to produce insulin-like growth factor 1 (IGF-1), the main mediator of its anabolic effects; GH itself is also directly lipolytic, promoting fat breakdown.

Somatropin’s authorised indications and eligible patients depend on the named product and country. Use the prescribing information for the exact product. SupStack does not recommend somatropin for self-directed anti-ageing or performance use.

In adults with confirmed GH deficiency the replacement evidence is real and randomized — a systematic review and meta-analysis of 54 RCTs (Hazem 2012) found GH reduced weight and body-fat content, increased lean body mass, and improved quality of life in most trials, at the cost of more edema and joint stiffness.

That is the indication-bounded case. The rest of GH's fame is the problem the evidence here corrects.

Its reputation as an anti-aging and physique/performance drug rests largely on Daniel Rudman's small 1990 New England Journal of Medicine study, in which six months of GH in men over 60 increased lean body mass by about 9% and decreased fat mass by about 14% — a body-composition signal that launched a multi-billion-dollar 'anti-aging' industry, even though Rudman's own later commentary and the NEJM editors warned the result was being misused.

When the question was tested rigorously, the anti-aging story collapsed.

The Blackman 2002 JAMA randomized trial in healthy older men and women found GH (with or without sex steroids) did increase lean mass and reduce fat, but produced little or no gain in strength or endurance in women, only marginal strength gains in men, and a high burden of adverse effects — edema, carpal tunnel symptoms, arthralgias, and notably diabetes or glucose intolerance (18 GH-treated men vs 7 not on GH).

The decisive evidence is Hauashia Liu's two systematic reviews in the Annals of Internal Medicine: the 2007 review of GH in the healthy elderly concluded GH causes only small body-composition changes, increases adverse events (soft-tissue edema, arthralgias, carpal tunnel syndrome, gynecomastia, and a trend to diabetes/impaired fasting glucose), and 'cannot be recommended as an antiaging therapy'; the 2008 review of GH and athletic performance concluded that claims GH enhances physical performance 'are not supported by the scientific literature' — lean mass rose but strength and exercise capacity did not, and exercise capacity may even worsen.

The one athletic signal, from the WADA-funded Meinhardt 2010 randomized trial, was a small (~4%) increase in sprint capacity, with no improvement in strength, power, or VO2max, and it disappeared within six weeks of stopping.

So across healthy older adults and athletes, the honest picture is: modest body-composition change with no proven functional benefit, bought with a meaningful rise in adverse events. The harms are not trivial.

GH antagonizes insulin and reliably impairs glucose tolerance and can precipitate diabetes; it causes fluid retention (edema), arthralgias, and carpal tunnel syndrome; chronic GH excess (as in acromegaly) causes organomegaly — the so-called 'GH gut'/visceral and organ enlargement physique seen in heavy users — cardiomyopathy, and is associated with increased mortality and cancer concern, which is why GH/IGF-1 axis stimulation is avoided in active malignancy and why long-term safety of non-deficient use is genuinely uncertain.

Legally and definitionally this matters: GH is a prescription drug, not a dietary supplement, and GH is banned in sport by WADA at all times.

The score reflects this split: real, randomized benefit for diagnosed GH deficiency (body composition, quality of life), against an anti-aging reputation that the best evidence — the Liu systematic reviews — actively refutes, an athletic signal that is minimal, documented metabolic, fluid, joint, and organ harms, and a prescription-only status.

HGH is a hormone drug, not a supplement, and not a validated anti-aging or performance agent.